Immutep Announces Update From Placebo-Controlled, Double-Blind First-In-Human Phase I Study In Healthy Participants Evaluating IMP761, LAG-3 Agonist Antibody For Autoimmune Diseases

• Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levels
   
• Dose dependent immunosuppressive effect against a strong foreign antigen observed with continued favourable safety profile
   
• Substantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseases
   
• Given encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026 including presentation of data at a major medical conference
   

 SYDNEY, AUSTRALIA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces a positive update from the placebo-controlled, double-blind first-in-human Phase I study in healthy participants evaluating IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases.

The single-ascending dose escalation portion of the trial has successfully completed the 2.5 and 7 mg / kg dosing levels of IMP761 with continued positive safety and efficacy data. IMP761 was tolerated well with no treatment-related adverse reactions beyond mild intensity. Additionally, evidence of dose dependent immunosuppressive effects with IMP761 was observed with significant, long-lasting inhibition of the three T-cell-mediated intradermal reactions to a strong foreign antigen at day 2, 9 and 23.